AstraZeneca Shows It Can Still Take Some Knocks

AstraZeneca Plc has had another setback in the lab. That the British drugmaker can take it in its stride shows that enough is going right for CEO Pascal Soriot to begin justifying his opposition to Pfizer Inc.’s 69.4 billion-pound ($89 billion) takeover approach four years ago.